Alumis Inc (ALMS) Actualités

Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005

– A-005 was well tolerated and demonstrated ability to cross blood-brain barrier – – Maximal TYK2 inhibition...

Form 8-K - Current report

Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical stage...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

– Presented data at EADV supporting potential of ESK-001 as differentiated oral treatment in immune-mediated...

Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage...

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

28-week data show ESK-001 was generally well tolerated and most patients treated with the top dose of 40 mg...

Alumis to Participate in Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage...

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

– Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis –...

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

– Co-primary endpoint of PASI 75 and sPGA 0/1 score at 24 weeks to serve as basis for U.S. regulatory...

Alumis Announces Pricing of Initial Public Offering

SOUTH SAN FRANCISCO, Calif., June 27, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (“Alumis” or the “Company”...